Analytical Data
-
基因名
SGCB
- Application
-
别名
SGCB;Beta-sarcoglycan
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q16585
-
表达区间
1-318aa
-
氨基酸序列
MAAAAAAAAEQQSSNGPVKKSMREKAVERRSVNKEHNSNFKAGYIPIDED RLHKTGLRGRKGNLAICVIILLFILAVINLIITLVIWAVIRIGPNGCDSM EFHESGLLRFKQVSDMGVIHPLYKSTVGGRRNENLVITGNNQPIVFQQGT TKLSVENNKTSITSDIGMQFFDPRTQNILFSTDYETHEFHLPSGVKSLNV QKASTERITSNATSDLNIKVDGRAIVRGNEGVFIMGKTIEFHMGGNMELK AENSIILNGSVMVSTTRLPSSSSGDQLGSGDWVRYKLCMCADGTLFKVQV TSQNMGCQISDNPCGNTH
-
分子量
61 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SGCB (Sarcoglycan Beta) is a member of the sarcoglycan complex, which plays a crucial role in the structural integrity and function of muscle tissue. Research into SGCB has gained significant attention due to its association with various forms of muscular dystrophy, particularly limb-girdle muscular dystrophy type 2E (LGMD2E). Mutations in the SGCB gene can lead to the destabilization of the dystrophin-associated protein complex, resulting in muscle fiber damage and progressive muscle weakness. Understanding the molecular mechanisms underlying SGCB dysfunction is essential for identifying potential therapeutic strategies. Recent advances in gene therapy, protein replacement, and CRISPR-Cas9 technology have opened new avenues for addressing SGCB-related muscle disorders. Investigating the structure-function relationship of SGCB, its interactions with other components of the sarcoglycan complex, and its role in muscle cell signaling pathways can provide insights into the pathophysiology of muscular dystrophies. Additionally, animal models and patient-derived cell lines are being increasingly utilized to study SGCB's function and the impact of specific mutations, facilitating the development of targeted treatments. Therefore, ongoing research into SGCB not only enhances our understanding of muscle biology but also holds promise for innovative therapeutic interventions in muscle degenerative diseases.
